Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

BACKGROUND: The aim of this open label phase II study (NCT00407459) was to assess the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceresoli, G L, Zucali, P A, Mencoboni, M, Botta, M, Grossi, F, Cortinovis, D, Zilembo, N, Ripa, C, Tiseo, M, Favaretto, A G, Soto-Parra, H, De Vincenzo, F, Bruzzone, A, Lorenzi, E, Gianoncelli, L, Ercoli, B, Giordano, L, Santoro, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738125/
https://www.ncbi.nlm.nih.gov/pubmed/23860535
http://dx.doi.org/10.1038/bjc.2013.368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738125/
https://www.ncbi.nlm.nih.gov/pubmed/23860535
http://dx.doi.org/10.1038/bjc.2013.368

Ejemplares similares